SARS-CoV-2-Legionella Co-Infections: A Systematic Review and Meta-Analysis (2020-2021).

Matteo Riccò, Pietro Ferraro, Simona Peruzzi, Alessandro Zaniboni, Silvia Ranzieri
Author Information
  1. Matteo Riccò: AUSL-IRCCS di Reggio Emilia, Servizio di Prevenzione e Sicurezza Negli Ambienti di Lavoro (SPSAL), Local Health Unit of Reggio Emilia, 42122 Reggio Emilia, Italy. ORCID
  2. Pietro Ferraro: Servizio di Medicina del Lavoro, ASL di Foggia, 71121 Foggia, Italy. ORCID
  3. Simona Peruzzi: AUSL-IRCCS di Reggio Emilia, Laboratorio Analisi Chimico Cliniche e Microbiologiche, Ospedale Civile di Guastalla, 42016 Guastalla, Italy. ORCID
  4. Alessandro Zaniboni: Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
  5. Silvia Ranzieri: Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy. ORCID

Abstract

Legionnaires' Disease (LD) is a severe, sometimes fatal interstitial pneumonia due to . Since the inception of the SARS-CoV-2 pandemic, some contradictory reports about the effects of lockdown measures on its epidemiology have been published, but no summary evidence has been collected to date. Therefore, we searched two different databases (PubMed and EMBASE) focusing on studies that reported the occurrence of LD among SARS-CoV-2 cases. Data were extracted using a standardized assessment form, and the results of such analyses were systematically reported, summarized, and compared. We identified a total of 38 articles, including 27 observational studies (either prospective or retrospective ones), 10 case reports, and 1 case series. Overall, data on 10,936 SARS-CoV-2 cases were included in the analyses. Of them, 5035 (46.0%) were tested for either through urinary antigen test or PCR, with 18 positive cases (0.4%). A pooled prevalence of 0.288% (95% Confidence Interval (95% CI) 0.129-0.641), was eventually calculated. Moreover, detailed data on 19 co-infections LD + SARS-CoV-2 were obtained (males: 84.2%; mean age: 61.9 years, range 35 to 83; 78.9% with 1 or more underlying comorbidities), including 16 (84.2%) admissions to the ICU, with a Case Fatality Ratio of 26.3%. In summary, our analyses suggest that the occurrence of SARS-CoV-2- infections may represent a relatively rare but not irrelevant event, and incident cases are characterized by a dismal prognosis.

Keywords

References

  1. Microbes Infect. 2021 May-Jun;23(4-5):104806 [PMID: 33684520]
  2. J Med Virol. 2022 Jan;94(1):303-309 [PMID: 34491594]
  3. Rev Chilena Infectol. 2021 Aug;38(4):564-567 [PMID: 34652404]
  4. Infection. 2021 Dec;49(6):1299-1306 [PMID: 34687426]
  5. Lancet Reg Health Eur. 2021 Jul;6:100112 [PMID: 34124707]
  6. Acta Biomed. 2019 Sep 13;90(9-S):7-14 [PMID: 31517884]
  7. Euro Surveill. 2020 Nov;25(47): [PMID: 33243356]
  8. JA Clin Rep. 2021 Aug 18;7(1):62 [PMID: 34409491]
  9. Infect Dis Clin North Am. 2017 Mar;31(1):123-135 [PMID: 28159172]
  10. J Antimicrob Chemother. 2021 Feb 11;76(3):796-803 [PMID: 33185241]
  11. PLoS Med. 2009 Jul 21;6(7):e1000097 [PMID: 19621072]
  12. Ann Intensive Care. 2020 Sep 7;10(1):119 [PMID: 32894364]
  13. Nephrol Dial Transplant. 2016 Jun;31(6):882-5 [PMID: 27217394]
  14. Clin Microbiol Infect. 2021 Nov;27(11):1658-1665 [PMID: 34481722]
  15. Curr Environ Health Rep. 2018 Jun;5(2):263-271 [PMID: 29744757]
  16. Antibiotics (Basel). 2021 Nov 07;10(11): [PMID: 34827296]
  17. Lancet Microbe. 2020 Jun;1(2):e62 [PMID: 32835331]
  18. Infect Drug Resist. 2021 Jul 21;14:2795-2807 [PMID: 34321896]
  19. Acta Biomed. 2017 Oct 23;88(3):337-351 [PMID: 29083344]
  20. Clin Respir J. 2021 Jul;15(7):815-825 [PMID: 33818909]
  21. Ann Ist Super Sanita. 2021 Jul-Sep;57(3):199-200 [PMID: 34554112]
  22. J Med Virol. 2022 May;94(5):1920-1925 [PMID: 34951498]
  23. J Infect. 2020 Dec;81(6):952-960 [PMID: 32987097]
  24. J Intensive Care. 2021 Jan 18;9(1):10 [PMID: 33461613]
  25. Int J Epidemiol. 2021 Jan 23;49(6):1909-1917 [PMID: 33053172]
  26. JAMA Netw Open. 2020 Jan 3;3(1):e1919325 [PMID: 31922554]
  27. Infect Dis Now. 2022 Jun;52(4):208-213 [PMID: 34896662]
  28. Lancet. 2016 Jan 23;387(10016):376-385 [PMID: 26231463]
  29. JAC Antimicrob Resist. 2020 Sep;2(3):dlaa071 [PMID: 32864608]
  30. Diagn Microbiol Infect Dis. 2020 Dec;98(4):115199 [PMID: 32979617]
  31. Infect Genet Evol. 2016 Sep;43:108-22 [PMID: 27180896]
  32. Euro Surveill. 2020 Jul;25(30): [PMID: 32734857]
  33. Emerg Infect Dis. 2014 Nov;20(11):1795-1802 [PMID: 25513657]
  34. Microb Pathog. 2021 Jul;156:104941 [PMID: 33962007]
  35. Microbiol Spectr. 2021 Sep 3;9(1):e0016321 [PMID: 34287033]
  36. Healthcare (Basel). 2021 Nov 21;9(11): [PMID: 34828643]
  37. Nature. 2020 Aug;584(7820):257-261 [PMID: 32512579]
  38. Front Med (Lausanne). 2021 Jan 14;7:560685 [PMID: 33521004]
  39. Cureus. 2021 Mar 1;13(3):e13632 [PMID: 33816031]
  40. Infect Dis Clin North Am. 2017 Mar;31(1):167-178 [PMID: 27979684]
  41. N Engl J Med. 2001 Jun 21;344(25):1917-28 [PMID: 11419430]
  42. Infect Dis (Lond). 2022 Feb;54(2):134-144 [PMID: 34606393]
  43. Diagn Microbiol Infect Dis. 2021 Nov;101(3):115416 [PMID: 34391076]
  44. Antimicrob Resist Infect Control. 2021 Oct 30;10(1):155 [PMID: 34717761]
  45. Infect Dis (Lond). 2021 Feb;53(2):102-110 [PMID: 33103530]
  46. Acta Biomed. 2022 Mar 14;93(1):e2022090 [PMID: 35315385]
  47. Sci Rep. 2020 Apr 30;10(1):7337 [PMID: 32355282]
  48. Lancet Reg Health Eur. 2021 Jul;6:100139 [PMID: 34223441]
  49. Microorganisms. 2021 Oct 20;9(11): [PMID: 34835307]
  50. Infect Dis Clin North Am. 2017 Mar;31(1):137-153 [PMID: 28159173]
  51. Emerg Infect Dis. 2021 May;27(5):1535-1537 [PMID: 33900187]
  52. Clin Infect Dis. 2021 Jun 1;72(11):1979-1989 [PMID: 32296816]
  53. Epidemiol Infect. 2015 Aug;143(11):2416-25 [PMID: 25427871]
  54. JAMA. 2020 Apr 28;323(16):1545-1546 [PMID: 32167538]
  55. Euro Surveill. 2013 Jun 06;18(23): [PMID: 23787129]
  56. Eur J Clin Microbiol Infect Dis. 2021 Apr;40(4):859-869 [PMID: 33140176]
  57. Am J Emerg Med. 2022 Jan;51:1-5 [PMID: 34637995]
  58. Clin Infect Dis. 2020 Dec 3;71(9):2459-2468 [PMID: 32358954]
  59. Clin Microbiol Infect. 2020 Oct;26(10):1395-1399 [PMID: 32603803]
  60. Cureus. 2021 Jan 4;13(1):e12476 [PMID: 33552790]
  61. Proc Natl Acad Sci U S A. 2020 May 12;117(19):10484-10491 [PMID: 32327608]
  62. J Med Virol. 2021 Mar;93(3):1489-1495 [PMID: 32808695]
  63. Infect Control Hosp Epidemiol. 2021 Jan;42(1):84-88 [PMID: 32703320]
  64. Euro Surveill. 2021 Jun;26(25): [PMID: 34169817]
  65. J Travel Med. 2020 May 18;27(3): [PMID: 32297939]
  66. Am J Respir Crit Care Med. 2021 Sep 1;204(5):546-556 [PMID: 34038699]
  67. Annu Rev Pathol. 2020 Jan 24;15:439-466 [PMID: 31657966]
  68. Lancet Reg Health Eur. 2021 Jun 19;6:100103 [PMID: 34557831]
  69. Open Forum Infect Dis. 2020 Oct 22;7(11):ofaa484 [PMID: 33204762]
  70. Pneumonia (Nathan). 2021 Jan 6;13(1):2 [PMID: 33407911]
  71. Emerg Infect Dis. 2021 Nov;27(11):2864-2868 [PMID: 34469708]
  72. Virus Res. 2020 Aug;285:198005 [PMID: 32408156]
  73. J Med Microbiol. 2021 Apr;70(4): [PMID: 33861190]
  74. Intern Med. 2021 Dec 1;60(23):3709-3719 [PMID: 34544950]
  75. Infect Dis Clin North Am. 2017 Mar;31(1):7-27 [PMID: 28159177]
  76. Int J Antimicrob Agents. 2021 Oct;58(4):106409 [PMID: 34339777]
  77. Cureus. 2021 Aug 21;13(8):e17356 [PMID: 34567896]
  78. Emerg Infect Dis. 2021 Nov;27(11):2950-2952 [PMID: 34670660]
  79. Crit Care. 2020 Jul 9;24(1):410 [PMID: 32646494]
  80. Syst Rev. 2021 Jan 26;10(1):39 [PMID: 33499930]
  81. N Engl J Med. 2009 Feb 5;360(6):588-98 [PMID: 19196675]
  82. Enferm Infecc Microbiol Clin. 2022 Dec;40(10):578-579 [PMID: 34580551]
  83. Microorganisms. 2021 Nov 30;9(12): [PMID: 34946086]

Word Cloud

Created with Highcharts 10.0.0SARS-CoV-2casesLDanalyses0reportsepidemiologysummarystudiesreportedoccurrenceincludingeither10case1data95%842%Legionnaires'DiseaseseveresometimesfatalinterstitialpneumoniadueSinceinceptionpandemiccontradictoryeffectslockdownmeasurespublishedevidencecollecteddateThereforesearchedtwodifferentdatabasesPubMedEMBASEfocusingamongDataextractedusingstandardizedassessmentformresultssystematicallysummarizedcomparedidentifiedtotal38articles27observationalprospectiveretrospectiveonesseriesOverall936included5035460%testedurinaryantigentestPCR18positive4%pooledprevalence288%ConfidenceIntervalCI129-0641eventuallycalculatedMoreoverdetailed19co-infections+obtainedmales:meanage:619yearsrange3583789%underlyingcomorbidities16admissionsICUCaseFatalityRatio263%suggestSARS-CoV-2-infectionsmayrepresentrelativelyrareirrelevanteventincidentcharacterizeddismalprognosisSARS-CoV-2-LegionellaCo-Infections:SystematicReviewMeta-Analysis2020-2021COVID-19LegionellapneumophilatypingLegionnaires’diseasediagnosis

Similar Articles

Cited By